Nalaganje...
Optimized timing of using infliximab in perianal fistulizing Crohn's disease
Infliximab (IFX), as a drug of first-line therapy, can alter the natural progression of Crohn’s disease (CD), promote mucosal healing and reduce complications, hospitalizations, and the incidence of surgery. Perianal fistulas are responsible for the refractoriness of CD and represent a more aggressi...
Shranjeno v:
| izdano v: | World J Gastroenterol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Baishideng Publishing Group Inc
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7167413/ https://ncbi.nlm.nih.gov/pubmed/32327905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v26.i14.1554 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|